Virtual Gastrointestinal Endoscopy

Number: 0535

Table Of Contents

Policy
Applicable CPT / HCPCS / ICD-10 Codes
Background
References

---

Policy

Scope of Policy

This Clinical Policy Bulletin addresses virtual gastrointestinal endoscopy.

1. Medical Necessity

   1. Aetna considers virtual colonoscopy using computed tomography (CT colonography) performed every 5 years a medically necessary preventive service for colorectal cancer screening of average-risk asymptomatic persons 45 years of age or older.
   2. Aetna considers diagnostic virtual colonoscopy medically necessary for colonic evaluation of:
      
      
      • Symptomatic members with a known colonic obstruction when standard optical colonoscopy is contraindicated; or 
      • Symptomatic members with an incomplete colonoscopy (e.g., due to diverticulosis, obstructive or stenosing colonic lesions, or redundant colon); or
      • Members who are receiving chronic anti-coagulation that cannot be interrupted; or
      • Members with complications from prior optical colonoscopy; or
      • Members with active diverticulitis and an increased risk of perforation; or
      • Members with increased sedation risk (e.g., chronic obstructive pulmonary disease or previous adverse reaction to anesthesia); or
      • Members who are symptomatic and require colon examination less than 12 weeks after colon surgery.
   3. Aetna considers magnetic resonance enterography medically necessary for monitoring members with known inflammatory bowel disease (in particular, Crohn’s disease) when small bowel disease or penetrating disease complications are present (see CPB 0396 - Gastrointestinal Function: Selected Tests).

2. Experimental and Investigational

   1. Aetna considers virtual colonoscopy using CT experimental and investigational for all other indications not noted as medically necessary above including the following (not an all-inclusive list) because its clinical value for indications other than those listed above, has not been established:
      
      
      • Diagnosis of colorectal cancer or inflammatory bowel disease (Crohn's disease and ulcerative colitis) in persons without known colonic obstruction or an incomplete optical colonoscopy due to obstructive or stenosing colonic lesions, with or without diverticulosis;
      • Surveillance of colorectal cancer, or Lynch syndrome.
   2. Aetna considers virtual colonoscopy using magnetic resonance imaging (MRI) (also known as MRI colonography) experimental and investigational for the screening or diagnosis of colorectal cancer, diverticulitis, inflammatory bowel disease, or surveillance of Lynch syndrome, or other indications because its value for these indications has not been established.
   3. Aetna considers virtual upper gastrointestinal endoscopy using CT for the detection and evaluation of upper gastrointestinal lesions experimental and investigational because its value for these indications has not been established.

3. Related Policies

   • CPB 0396 - Gastrointestinal Function: Selected Tests

---

Table:

CPT Codes / HCPCS Codes / ICD-10 Codes

Code	Code Description
Information in the [brackets] below has been added for clarification purposes.   Codes requiring a 7th character are represented by "+":
Virtual Colonoscopy:
Diagnostic:
CPT codes covered if selection criteria are met:
74261	CT colonography, diagnostic, including image postprocessing; without contrast material
74262	with contrast material(s) including non-contrast images, if performed
Other HCPCS codes related to the CPB:
G0105	Colorectal cancer screening; colonoscopy on individual at high risk
G0106	Colorectal cancer screening; alternative to G0104, screening sigmoidoscopy, barium enema
G0120	Colorectal cancer screening; alternative to G0105, screening colonoscopy, barium enema
G0121	Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk
G0122	Colorectal cancer screening; barium enema
ICD-10 codes covered if selection criteria are met:
K56.50 - K56.52	Intestinal adhesions [bands] with obstruction (postinfection)
K56.600 - K56.699	Other and unspecified intestinal obstruction
K57.00 - K57.93	Diverticular disease of intestine
Q42.0 - Q42.9	Congenital absence, atresia and stenosis of large intestine
T41.0X5+, T41.1x5+, T41.205+, T41.295+, T41.3X5+, T41.45x+, T88.59x+	Adverse effect of anesthetics
Z79.01	Long term (current) use of anticoagulants [that cannot be interrupted]
Z88.4	Allergy status to anesthetic agent status
ICD-10 codes not covered for indications listed in the CPB:
C18.0 – C18.9	Malignant neoplasm of colon
C19	Malignant neoplasm of rectosigmoid junction
C20	Malignant neoplasm of rectum
D01.0 – D01.2	Carcinoma in situ of colon
Z12.11	Encounter for screening for malignant neoplasm of colon
Z15.09	Genetic susceptibility to other malignant neoplasm [Lynch Syndrome]
Z80.0	Family history of malignant neoplasm of digestive organs [Lynch Syndrome]
Screening:
CPT codes covered if selection criteria are met:
74263	CT colonography, screening, including image postprocessing
ICD-10 codes covered if selection criteria are met:
T41.0X5+, T41.1x5+, T41.205+, T41.295+, T41.3X5+, T41.45x+, T88.59x+	Adverse effect of anesthetics
Z00.00 - Z00.01	Encounter for general adult medical examination without/with abnormal findings
Z12.10 - Z12.12	Encounter for screening for malignant neoplasm of intestinal tract, colon, rectur
Z79.01	Long-term (current) use of anticoagulants [that cannot be interrupted]
Z88.4	Allergy status to anesthetic agent status
Virtual Upper Gastrointestinal (GI) Endoscopy:
CPT codes not covered for indications listed in the CPB:
Virtual upper gastrointestinal (GI) endoscopy- no specific code
ICD-10 codes not covered for indications listed in the CPB:
C15.3 - C17.0	Malignant neoplasm of esophagus, stomach, and duodenum
C78.4	Secondary malignant neoplasm of small intestine
D00.1 - D01.0	Carcinoma in situ of esophagus, stomach and colon
D01.49	Carcinoma in situ of other parts of intestine [duodenum]
D13.0 - D13.39	Benign neoplasm of esophagus, stomach, duodenum, jejunum, and ileum
D37.1 - D37.5	Neoplasm of uncertain behavior of stomach, intestines, and rectum
D37.8	Neoplasm of uncertain behavior of other digestive organs [esophagus]
D49.0	Neoplasm of unspecified nature of digestive system
K20.0 - K31.A29	Diseases of esophagus, stomach, and duodenum
K50.00 - K68.9	Noninfectious enteritis and colitis, and other diseases of intestines and peritoneum
Z12.13	Encounter for screening for malignant neoplasm of small intestine
MRI Colonography:
CPT codes not covered for indications listed in the CPB:
MRI Colonography - no specific code
ICD-10 codes not covered for indications listed in the CPB:
K57.20 - K57.33	Diverticulitis of large intestine [colon]
Z15.09	Genetic susceptibility to other malignant neoplasm [Lynch Syndrome]
Z80.0	Family history of malignant neoplasm of digestive organs [Lynch Syndrome]
Magnetic Resonance Enterography:
CPT codes covered if selection criteria are met:
72195	Magnetic resonance (eg, proton) imaging, pelvis; without contrast material(s)
72196	with contrast material(s)
72197	without contrast material(s), followed by contrast material(s) and further sequences
74181	Magnetic resonance (eg, proton) imaging, abdomen; without contrast material(s)
74182	with contrast material(s)
74183	without contrast material(s), followed by with contrast material(s) and further sequences
ICD-10 codes covered if selection criteria are met:
K50.00 – K50.919	Crohn's disease

---

Background

Virtual endoscopy combines the features of endoscopic viewing and computerized tomography (CT) data to create a virtual image that is artificially generated by a computer.  In the evaluation of gastrointestinal cancers, virtual endoscopy has been most commonly used in colorectal carcinomas and to a much lesser extent in gastric carcinomas.  The clinical application of virtual endoscopic techniques is also being used with other procedures such as bronchoscopy, gastroscopy, cystoscopy, sinus imaging, virtual angioscopy, and cerebral ventriculography (Oto, 2002; Dykes, 2001).

Virtual Colonoscopy

Computed tomographic colonography (CTC), also known as virtual colonoscopy, was developed as a minimally invasive method to examine the colon. This test has been suggested for use in screening and to detect abnormalities in the colon and rectum (eg, colorectal cancer [CRC] and polyps). It involves the use of helical computed tomography (CT) and computer generated images to produce high-resolution two- and three-dimensional (3D) images of the colon and rectum. Prior to virtual colonoscopy, standard bowel cleansing preparations are needed to evacuate any stool and fluid from the colon. During the procedure, a rectal tube is inserted and the colon is distended using room air or carbon dioxide and images are then taken by a helical CT scanner. Using a conventional workstation and a dynamic display of images, a radiologist conducts virtual examinations of the bowel, simulating the way endoscopists view the colon. The results are interpreted by a radiologist. If suspicious lesions are detected, the individual generally must undergo further testing via conventional colonoscopy. Virtual colonoscopy provides a method for processing data that can display computer images of the colon in a more anatomic life-like format and is being promoted by some as a non-invasive screening test for colorectal neoplasia.

The U.S. Preventive Services Task Force (USPSTF, 2016) recommends screening for colorectal cancer starting at age 50 years and continuing until age 75 years (A recommendation). The USPSTF stated that the decision to screen for colorectal cancer in adults aged 76 to 85 years should be an individual one, taking into account the patient’s overall health and prior screening history (C recommendation). The USPSTF concluded with high certainty that screening for colorectal cancer in average-risk, asymptomatic adults aged 50 to 75 years is of substantial net benefit.

The USPSTF (2016) stated that their recommendation for those considered "average-risk" are for individuals who do not have a family history of known genetic disorders that predispose them to a high lifetime risk of colorectal cancer (CRC) such as Lynch syndrome or familial adenomatous polyposis, have a personal history of inflammatory bowel disease, have had a previous adenomatous polyp, or have had previous CRC.  Populations at increased risk include patients with a family history of CRC, such as a first-degree relative with early-onset CRC or multiple first-degree relatives with the disease.

The USPSTF (2016) listed CT colonography performed every 5 years as an acceptable colorectal cancer screening strategy for average-risk persons. The USPSTF stated that multiple screening strategies are available to choose from, with different levels of evidence to support their effectiveness, as well as unique advantages and limitations, although there are no empirical data to demonstrate that any of the reviewed strategies provide a greater net benefit. 

The USPSTF (2016) found that the evidence for assessing the effectiveness of computed tomography (CT) colonography is limited to studies of its test characteristics. The USPSTF noted that computed tomography colonography can result in unnecessary diagnostic testing or treatment of incidental extracolonic findings that are of no importance or would never have threatened the patient’s health or become apparent without screening (ie, overdiagnosis and overtreatment). The USPSTF noted that extracolonic findings are common, occurring in about 40% to 70% of screening examinations. Between 5% and 37% of these findings result in diagnostic follow-up, and about 3% require definitive treatment. As with other screening strategies, indirect harms from CT colonography can also occur from follow-up colonoscopy for positive findings.

The USPSTF (2016) stated that radiation-induced cancer is a potential long-term concern with repeated use of CT colonography. No studies directly measured this risk, but radiation exposure during the procedure seems to be low, with a maximum exposure of about 7 mSv per examination. In comparison, annual background radiation exposure in the United States is 3 mSv per year per person.

Virtual colonoscopies should only be performed at centers with an appropriate generation of CT scan – a minimum 4 detector CT scanner; collimation of 3 mm or less, overlapping sections at an interval that is 2/3 or less of the collimation, and scan times should be 30 seconds or less in order to minimize respiratory motion.

Pickhardt et al (2003) reported that CT virtual colonoscopy with the use of a three-dimensional (3-D) approach is an accurate screening method for the detection of colorectal neoplasia in asymptomatic average-risk adults and compares favorably with optical colonoscopy in terms of the detection of clinically relevant lesions.  However, in an editorial that accompanied the study by Pickhardt et al, Morrin and LaMont (2003) stated that "if the results of this well-designed study are reproducible on a wider scale, and if the important questions regarding the appropriate size threshold and surveillance of smaller polyps can be resolved, then screening virtual colonoscopy is ready for prime time".

A study by Cotton et al (2004) reported that the accuracy of CT colonography (virtual colonoscopy) for the detection of colorectal cancer is less reliable than previously thought.  CT colonography involves the examination of computer-generated images of the colon constructed from data obtained from an abdominal computed tomographic examination.  Several studies have suggested a high degree of sensitivity for CT colonography; however, those results were obtained at single, specialized centers.  Cotton reported on a new study that was designed to evaluate the accuracy of CT colonography in routine practice at 9 major hospital centers.

In this study, researchers assessed the accuracy of CT colonography in 615 patients aged 50 years or older who were referred for routine, clinically indicated colonoscopy (Cotton et al, 2004).  Colonoscopy was performed within 2 hours of the colonography and results were compared.  The sensitivity of CT colonography for detecting 1 or more lesions sized at least 6 mm was 39 % and for lesions sized at least 10 mm, it was 55 %.  These results were significantly lower than those for conventional colonoscopy, with sensitivities of 99 % and 100 %, respectively.  CT colonography missed 2 of 8 cancers.  The accuracy of CT colonography varied considerably between centers.  At the 1 center that had "substantial" prior experience with CT colonography, the sensitivity was 82 % for lesions of 6 mm or more.  Sensitivity at all of the other centers combined was 24 %, with no improvement in accuracy as the number of cases at each center was increased.  Preference questionnaires after both procedures were performed showed that 46 % of the patients preferred CT colonography versus 41 % who preferred conventional colonoscopy. The authors stated that "even if the results of CT colonography continue to be good in the hands of experts, it has yet to be proven that this expertise can be taught and disseminated reliably into daily practice".  The authors concluded that CT colonography is not yet ready for widespread clinical application; techniques and training need to be improved.

The American Cancer Society guidelines on colorectal cancer screening recommend several methods of screening, including virtual colonoscopy, based in part upon the presumption that the availability of multiple methods of screening will improve compliance (Levin et al, 2008).  Colorectal cancer screening guidelines from the American Cancer Society recommend CT colonography (virtual colonoscopy) performed every 5 years as an acceptable alternative to optical colonoscopy performed every 10 years for screening of average-risk persons.  Virtual colonoscopy is similar to optical colonoscoppy in that it requires completion of a pre-procedure cathartic regimen.  If a lesion in found on virtual colonoscopy, the patient must return another day and complete another cathartic regimen for an optical colonoscopy to remove the lesion.  By contrast, optical colonoscopy allows for identification and removal of a lesion in 1 procedure.

An assessment of CT colonography prepared by the Institute for Clinical and Economic Review (ICER) for the Washington State Health Care Authority (Scherer et al, 2008) found that, in direct comparison to optical colonoscopy, CT colonography every 10 years is substantially more expensive and marginally less effective in preventing cases of cancer (47 versus 52 in a lifetime cohort of 1,000 individuals) and cancer deaths (24 versus 26).  The investigators reported that only 1 CT colonography screening strategy is as effective as optical colonoscopy every 10 years, and that strategy is to perform CT colonography every 5 years with colonoscopy referral for polyps greater than 6 mm.  For this strategy, the cost per life-year gained for CT colonography versus optical colonoscopy was $630,700. The assessment noted that the preponderance of the data suggests that, among patients who experienced both CTC and colonoscopy, a small majority preferred CT colonoscopy. The assessment stated that it is unclear whether preferences elicited among some patients for CTC would result in a larger number of unscreened individuals in a population being screened. The review found no studies examining whether the availability of CT colonography results in increased numbers of individuals being screened within a population. 

ICER (2008) prepared an update to their assessment after publication of the National CT Colonography Trial, conducted by the American College of Radiology Imaging Network (ACRIN) (citing Johnson, et al., 2008). In the ACRIN study, the largest multicenter study of CTC published to date, over 2,500 asymptomatic patients were scheduled for optical colonoscopy at 15 clinical sites across the U.S. Patients first received CTC, followed by same-day colonoscopy in most cases. CTC sensitivity and specificity for detecting polyps ≥ 10 mm in size were 90% and 86%. Sensitivity and specificity for polyps ≥ 6 mm were somewhat lower (78%, 88%). The range of sensitivity across individual radiologist interpreters was 67%-100%. Extracolonic findings were reported in 66% of the participants; 16% were deemed to require either additional evaluation or urgent care. No data on the subsequent outcomes or costs due to incidental findings were reported. The ICER update noted that a key new piece of evidence given in this study is the relatively broad range of performance across radiologists, all of whom received special training in CTC evaluation and/or had performed more than 500 interpretations. The ICER updated stated that decision-makers should consider whether the variability in performance demonstrated in the ACRIN study suggests that the actual performance in the general community is likely to be lower than that reported in this study. The ICER assessment stated that other questions remain unanswered, such as the effects of a cumulative radiation dose from CTC tests every 5-10 years as well as the impact of extracolonic findings from CTC on net health benefits and cost-effectiveness within the population.

Rex and colleagues (2009) updated the American College of Gastroenterology (ACG)'s recommendation on colorectal cancer (CRC) screening.  The CRC screening tests are now grouped into cancer prevention tests and cancer detection tests.  Colonoscopy every 10 years, beginning at age 50, remains the preferred CRC screening strategy.  It is recognized that colonoscopy is not available in every clinical setting because of economic limitations.  It is also realized that not all eligible persons are willing to undergo colonoscopy for screening purposes.  In these cases, patients should be offered an alternative CRC prevention test (flexible sigmoidoscopy every 5 to10 years, or a CT colonography every 5 years) or a cancer detection test (fecal immunochemical test for blood, FIT).

On May 12, 2009, the Centers for Medicare & Medicaid Services (CMS) issued a final coverage determination that refused coverage of CTC for colorectal screening.  It stated that the evidence is inadequate to conclude that CTC is an appropriate colorectal cancer screening test.

A number of studies have reported on individuals expressed preferences for colorectal cancer screening with CTC versus optical colonoscopy (see, e.g., Hawley et a., 2008; Moawad, et al, 2010).  It is unclear whether preferences elicited among some patients for CTC would result in a larger number of unscreened individuals in a population being screened.

A randomized controlled trial from the Netherlands (Stoop et al, 2012) found that the diagnostic yield for advanced neoplasia was similar for CT colonography and colonoscopy. Participation in colorectal cancer screening with CT colonography was significantly better than with colonoscopy, but colonoscopy identified significantly more advanced neoplasia per 100 participants than did CT colonography. The randomized controlled clinical trial (de Wijkerslooth, et al., 2012) also found that people invited to screening via CT colonography perceived the procedure (ahead of it) as less burdensome than colonoscopy. After actually having undergone the procedure, CT colonography screenees perceived it as having been more burdensome than colonoscopy screenees. Intended participation in a future round of screening was comparable. Rex (2012) commented on these studies, noting that the generalizability of these results to the U.S. population is uncertain because the use of screening colonoscopy is much more widespread in the U.S. than Europe. Nevertheless, these findings suggest that, over time, the reputation of CT colonography from the standpoint of patient burden and acceptability, even using the noncathartic approach, would likely diminish relative to colonoscopy (Rex, 2012). In addition, these results do not take into account that patients had no knowledge of test performance, which was substantially better for colonoscopy than CT colonography. Rex stated that understanding test performance characteristics is bound to influence the relative acceptability of the two tests.

Several studies have compared the results of CTC in the elderly, finding performance similar to CTC in the nonelderly population (Johnson et al, 2012; Cash et al, 2012; Macari et al, 2011; Kim et al, 2010).

Keegan et al (2010) evaluated the ability of CTC to perform at high levels of sensitivity and specificity for CRC screening in an asymptomatic population.  Searches were done in PubMed, Cochrane Library, TRIP Database, and UpToDate, utilizing the terms CT colonography, colonoscopy, virtual colonoscopy, screening, and colon cancer.  In PubMed the following limits and terms were used: published in the last 5 years, humans, meta-analysis, randomized controlled trial, and English.  A meta-analysis by Mulhall et al revealed 2 studies meeting inclusion/exclusion criteria: Pickhardt et al and Macari et al.  Searching Pickhardt et al through "related articles" in PubMed yielded the Wessling et al study.  The authors concluded that CTC can achieve high accuracy, but only under specific conditions using multi-detector CT scanners, primary 3-D data interpretation, well-prepared patients, collimation of less than or equal to 1.25 mm, and data interpretation by an experienced radiologist.  They stated that cost-effectiveness and compliance in the general population, as well as radiation exposure and follow-up requirements with colonography for CRC screening, need further study.

Rockey (2010) stated that CTC has received considerable attention in the last decade as a colon-imaging tool.  The technique has also been proposed as a potential primary colon cancer-screening method in the United States.  The accuracy of the technique for the detection of large lesions seems to be high, perhaps in the range of colonoscopy.  Overall, the field is rapidly evolving.  Available data suggest that CTC, although a viable colon cancer screening modality in the United States, is not ready for widespread implementation, largely because of the lack of standards for training and reading and the limited number of skilled readers.

Kolligs (2012) stated that the highest evidence for all screening tests has been demonstrated for guaiac-based fecal occult blood testing.  Colonoscopy is a diagnostic and therapeutic tool and it serves as the reference standard for other tests in clinical studies.  Fecal immunochemical tests have a higher sensitivity than guaiac-based tests.  Several novel techniques are under development and could be adopted by screening programs in the future.  Next to colonoscopy, CTC and colon capsule endoscopy have the highest sensitivity for colorectal neoplasia.  Molecular tests that are based on the detection of genetic and epigenetic changes of DNA released by the tumor into feces or blood have a high potential and could potentially replace occult blood tests in the future. The author concluded that colonoscopy is the primary instrument for screening for colorectal neoplasia. Fecal occult blood testing should only be performed if colonoscopy is denied and CTC has not yet been approved for screening in Germany.

Members of an advisory panel convened by the U.S. Food and Drug Administration (FDA, 2013) were in agreement that radiation patients receive in CT colonography is not likely to be significant. Some FDA panelists expressed concern that CT colonography is less sensitive in smaller polyps less than 6 millimeters. Others noted that CT colonography was not able to reliably detect "flat" or serrated polyps, which may contribute to 30% of all colon cancers.  Panelists also expressed concern that untrained professionals would be reading the CTC and missing possible lesions that need follow-up. The benefits and harms of detection of extracolonic findings were also discussed. Panelists suggested that CT colonography may provide a useful option for patients who have contraindications to sedation or those on anticoagulants.

The AIM Specialty Health’s appropriate use criteria on "Imaging of the abdomen & pelvis" (2014) stated that indications for diagnostic CT colonography included the following:

• Complications from prior fiberoptic colonoscopy
• Diverticulitis, with increased risk of perforation
• Failed or incomplete fiberoptic colonoscopy of the entire colon, due to inability to pass the colonoscope proximally
• Increased sedation risk (e.g., chronic obstructive pulmonary disease or previous adverse reaction to anesthesia)
• Known colonic obstruction, when standard fiberoptic colonoscopy is contraindicated
• Lifetime or long-term anticoagulation, with increased patient risk if discontinued.

The American College of Radiology’s Appropriateness Criteria on "Left lower quadrant pain – suspected diverticulitis" (McNamara et al, 2014) stated that "In the future, less invasive examinations may become clinically relevant, including quantitative CT perfusion studies, diffusion-weighted MRI, and MR colonography".

Villa and colleagues (2015) stated that a thorough and complete colonoscopy is critically important in preventing colorectal cancer. Factors associated with difficult and incomplete colonoscopy include a poor bowel preparation, severe diverticulosis, redundant colon, looping, adhesions, young and female patients, patient discomfort, and the expertise of the endoscopist.  For difficult colonoscopy, focusing on bowel preparation techniques, appropriate sedation and adjunct techniques such as water immersion, abdominal pressure techniques, and patient positioning can overcome many of these challenges.  Occasionally, these fail and other alternatives to incomplete colonoscopy have to be considered.  If patients have low risk of polyps, then non-invasive imaging options such as CTC can be considered.  Novel applications such as Colon Capsule and Check-Cap are also emerging.  In patients in whom a clinically significant lesion is noted on a non-invasive imaging test or if they are at a higher risk of having polyps, balloon-assisted colonoscopy can be performed with either a single- or double-balloon enteroscope or colonoscope.  The application of these techniques enables complete colonoscopic examination in the vast majority of patients.

Detection of Proximal Colon Polyps and Proximal Synchronous Colorectal Cancer

Heo and associates (2017) stated that virtual colonoscopy is the most recently developed tool for detecting colorectal cancers and polyps, but its effectiveness is limited.  These investigators compared the result of pre-operative virtual colonoscopy to result of pre-operative and post-operative conventional colonoscopy.  In addition, they evaluated the accuracy of pre-operative virtual colonoscopy in patients who had obstructive colorectal cancer that did not allow colonoscopy.  A total of 164 patients who had undergone pre-operative virtual colonoscopy and curative surgery after the diagnosis of a colorectal adenocarcinoma between November 2008 and August 2013 were pooled.  These researchers compared the result of conventional colonoscopy with that of virtual colonoscopy in the non-obstructive group and the results of pre-operative virtual colonoscopy with that of post-operative colonoscopy performed at 6 months after surgery in the obstructive group.  Of the 164 patients, 108 were men and 56 were women; the mean age was 62.7 years.  The average sensitivity, specificity, and accuracy of virtual colonoscopy for all patients were 31.0 %, 67.2 %, and 43.8 %, respectively.  In the non-obstructive group, the average sensitivity, specificity, and accuracy were 36.6 %, 66.2 %, and 48.0 %, respectively, whereas in the obstructive group, they were 2 %, 72.4 %, and 25.4 %.  Synchronous cancer was detected via virtual colonoscopy in 4 of the 164 patients.  The authors concluded that virtual colonoscopy alone is a limited imaging tool for detecting proximal colon polyps.  However, in patients with obstructive colorectal cancer, its use may have a limited benefit in detecting proximal synchronous colorectal cancer.

Magnetic Resonance Colonography

Magnetic resonance (MR) colonography is a diagnostic test generally performed by a radiologist and is purported to be utilized to detect colorectal polyps and CRC. This outpatient procedure also requires standard bowel cleansing preparations. The colon is then distended with a contrast medium that has been placed via a rectal tube. Magnetic resonance imaging (MRI) data reportedly creates a 3D image of the interior surface of the colon.

An assessment by the Ontario Ministry of Health and Long-Term Care (2009) concluded that magnetic resonance colonography (MRC) and CTC with 16-slice or 64-slice scanners have equal sensitivity for the detection of colorectal cancer, as well as for the detection of large and medium sized polyps; however, MRC does not carry the associated risks of ionizing radiation.  The assessment found that MRC and CTC with 16-slice or 64-slice scanners can reliably detect most colorectal cancers and large colorectal polyps; however, about 20 % of medium-sized colorectal polyps will be missed by both techniques.  The report found, however, that none of the techniques can reliably detect small polyps and MRC has a much lower sensitivity for the detection of small polyps compared with CTC.

Graser et al (2013) examined if MRC can be used to screen for colorectal adenomas and cancers.  These investigators analyzed data from 286 asymptomatic adults (40 to 82 years old) who underwent 3 Tesla MRC and colonoscopic examinations on the same day.  Fecal occult-blood testing (FOBT) was performed before bowel preparation.  Colonoscopists were initially blinded to the findings on MRC and unblinded after withdrawal from the respective segments.  Sensitivities for adenoma and per-patient sensitivities and specificities were calculated based on the unblinded results of colonoscopy.  These researchers detected 133 adenomas and 2 cancers in 86 patients; 37 adenomas were greater than or equal to 6 mm, and 20 adenomas were advanced.  Sensitivities of MRC and colonoscopy for adenomas greater than or equal to 6 mm were 78.4 % (95 % confidence interval [CI]: 61.8 to 90.2) and 97.3 % (95 % CI: 85.8 to 99.9); for advanced adenomas these values were 75 % (95 % CI: 50.9 to 91.3) and 100 % (95 % CI: 83.2 to 100.0), respectively.  Magnetic resonance colonography identified 87.1 % (95 % CI: 70.2 to 96.4), colonoscopy 96.8 % (95 % CI: 83.3 to 99.9), and FOBT 10.0 % (95 % CI: 2.1 to 26.5) of individuals with adenomas greater than or equal to 6 mm and 83.8 % (95 % CI: 58.6 to 96.4), 100 % (95 % CI: 81.5 to 100.0), and 17.6 % (95 % CI: 3.8 to 43.4) of individuals with advanced neoplasia.  Specificities of MRC, colonoscopy, and FOBT for individuals with adenomas greater than or equal to 6 mm were 95.3 % (95 % CI: 91.9 to 97.5), 96.9 % (95 % CI: 93.9 to 98.6), and 91.8 % (95 % CI: 87.6 to 94.9), respectively.  The authors concluded that 3 Tesla MRC detects colorectal adenomas greater than or equal to 6 mm and advanced neoplasia with high levels of sensitivity and specificity.  Although MRC detects colorectal neoplasia with lower levels of sensitivity than colonoscopy, it strongly outperforms one-time FOBT.

Virtual Upper Endoscopy

Virtual upper endoscopy is a noninvasive procedure that reportedly uses 3D imaging and CT to capture detailed pictures of the inside surfaces of organs of the gastrointestinal (GI) tract and simulates conventional upper endoscopy images. Virtual upper endoscopy is purported to diagnose the etiology of symptoms such as nausea, gastric reflux, abdominal pain and unexplained weight loss as well as identifying inflammation, ulcers, precancerous conditions and hernias. Individuals undergoing a virtual upper endoscopy do not need to have anesthesia administered. It is suggested that when the procedure is completed, the interpreting physician has the capability to modify the captured pictures by magnifying the images or altering the image angles.

Potential clinical applications of virtual upper GI endoscopy include the evaluation of early gastric carcinoma, advanced gastric carcinoma, leiomyoma, lymphoma, and benign ulcer.  For dedicated imaging of the stomach, an oral contrast agent (e.g., water) is administered to opacify and distend the stomach and GI tract and an intravenous contrast agent is used (e.g., Omnipaque 350) for complete evaluation.

Virtual upper GI endoscopy has not been studied as extensively as virtual colonoscopy.  A limited number of studies have been published and most of these studies have been conducted outside the United States involving small numbers of patients.  Early reports of 3-D imaging of the stomach by spiral CT were limited to shaded-surface display (Ogata et al, 1999).  However, the development of multidetector row scanners has improved the visualization of subtle tumors by allowing thinner collimation.  The detection rate of gastric lesions using virtual GI endoscopy has been reported to be between 73 % to 96.7 % in early gastric cancer and between 90 % to 100 % in advanced gastric cancer (Kim et al, 2001; Bhandari et al, 2004).  The overall accuracy, sensitivity, and specificity for endoscopic ultrasound and 3-D multi-detector row CT in the pre-operative determination of depth of invasion of gastric cancer (T stage) have been reported to be 87.5 %, 82.4 %, and 96 %; and 83.3 %, 69.1 %, and 94.4 %, respectively.  The accuracy, sensitivity, and specificity of endoscopic ultrasound and 3-D multi-detector row CT for lymph node staging were reported to be 79.1 %, 57 %, and 89.5 %; and 75 %, 57.4 %, and 89.3 %, respectively (Bhandari et al, 2004).

In a prospective study, Kim et al (2005) evaluated the accuracy of multi-detector row CT gastrography for the pre-operative staging of gastric cancer, with pathologic and surgical results as the reference standard.  A total of 106 patients with endoscopically proved gastric cancer underwent unenhanced and contrast material-enhanced multi-detector row CT gastrography, with effervescent granules used as oral contrast material.  Gastric cancer was detected in 92 (87 %) of 106 patients with transverse CT imaging and in 104 (98 %) with volumetric CT imaging.  The overall accuracy of the tumor staging was 77 % with transverse CT imaging and 84 % with volumetric CT imaging (p < 0.001). The overall accuracy for lymph node staging was 62 % with transverse CT imaging and 64 % with volumetric CT imaging (p = 0.057).  For staging of metastases, there was no difference between transverse and volumetric CT imaging (86 % for both) (p > 0.99).  The authors concluded that multi-detector row CT gastrography with multi-planar reformation and virtual endoscopy, compared with transverse CT imaging, can improve the accuracy of preoperative staging of gastric cancer.  This difference was significant for tumor staging but not for the staging of lymph nodes and metastases.

A prospective study of the pre-operative assessment of gastric cancer tumors using 32-multi-detector row CT was carried out by Kikuchi et al (2006) on patients (n = 74) with adenocarcinoma of the stomach (T1 tumors, n = 38; T2 and T3 tumors, n = 36).  In 35 (47 %) out of the 74 patients, the primary lesions could be detected on 2-D images obtained by CT.  In these patients, virtual endoscopic images of these tumors could be created.  A total of 27 advanced cancer tumors (75 %) were assessed based on 2-D CT images and 27 larger tumors (greater than 40 mm) (69 %) were assessed based on 2-D CT images.  Significant differences were found with respect to depth of tumor (p < 0.0001) and tumor size (p < 0.0001) between tumors that could or could not be assessed on multi-detector CT.  The authors concluded that future studies are required to fully explore the ability of multi-detector CT to assess tumor volume in advanced gastric cancer cases and to determine the optimum application of this approach.

In a prospective study, Mazzeo et al (2004) assessed the diagnostic capabilities of multi-detector CT in various esophageal pathologic conditions.  A total of 33 patients underwent a multi-detector CT study after esophageal distention by means of effervescent powder administered after induction of pharmacologic esophageal hypotonia.  All acquired images were post-processed with 2-D and 3-D software tools.  The CT data were compared with the results of conventional radiology (n = 33), endoscopy (n = 28), endoscopy ultrasonography (n = 14), or surgery (n = 14).  Follow-up ranged between 4 and 15 months.  Final diagnoses were leiomyoma (n = 6), squamous cell carcinoma (n = 6), adenocarcinoma (n = 4), esophageal infiltration by thyroid cancer (n = 1), benign polyposis (n = 2), chronic esophagitis (n = 5),  post-sclerotherapy stenosis (n = 1), and no abnormalities (n = 7).  Pathologic wall thickening was observed in 25 of 33 cases (76 %), with values ranging between 3.6 and 36 mm (mean, 9.6 mm).  Spiral CT demonstrated 21 true-positive cases, and 7 true-negative cases.  There were 4 false-negative cases and 1 false-positive case.  Sensitivity was 84 %, specificity was 87 %, diagnostic accuracy was 85 %, positive-predictive value was 95 %, and negative-predictive value was 64 %.  The authors concluded that evaluation of the esophagus with multi-detector CT is a promising technique and easy to use, allowing panoramic exploration, virtual endoluminal visualization, accurate longitudinal and axial evaluations, and simultaneous evaluation of T (tumor penetration) and N (lymph node involvement) parameters.

The first virtual gastroscopy study in North American patients assessed the feasibility of performing virtual gastroscopy on 10 patients with no reported GI abnormalities.  The authors stated that the anatomy of the stomach including the lumen, the cardia, the pylorus, gastric folds and the incisura angularis were well-visualized using 3-D spiral CT.  It was not possible to visualize the esophagus by virtual endoscopy because of difficulties keeping the lumen patent long enough to provide accurate imaging.  The authors concluded that further development is needed before virtual gastroscopy can be considered for clinical application (Ezzeddine et al, 2006).

Virtual gastroscopy is also being evaluated to assess the gastric mucosa in patients who have undergone laparoscopic Roux-en-Y gastric bypass.  One small case series reported promising results (Alva et al, 2008).

Conventional upper GI endoscopy provides direct visualization of the mucosa, permits evaluation of color changes that may be indicative of pathology, and suspicious lesions can be biopsied and the tissue sample evaluated histologically.  While virtual upper GI endoscopy using CT is a promising method for the detection and evaluation of upper GI lesions, randomized controlled studies comparing it to conventional upper GI endoscopy are needed to determine its clinical value.

Combination of Computed Tomography-Based Virtual Colonoscopy with Magnetic Resonance Imaging in Women Managed for Colorectal Endometriosis

In a retrospective study using prospectively recorded data, Mehedințu and colleagues (2018) examined if combining CT-based virtual colonoscopy (CTC) with MRI improves pre-operative assessment of colorectal endometriosis.  A total of 71 women treated for colorectal endometriosis managed between June 2015 and May 2016 were included in this analysis.  Patients included in this study underwent colorectal surgery for deep endometriosis infiltrating the rectum or the sigmoid colon and had pre-operative assessment using MRI and CTC.  To establish the correlation between pre-operative and intra-operative findings, the concordance kappa index was used.  Pre-operative data provided by MRI, CTC, and a combination of both were compared with intra-operative findings.  All 71 patients had a total of 105 endometriotic intestinal lesions intra-operatively confirmed.  Some 71.2 % of rectal nodules and 60.0 % of sigmoid nodules infiltrated the muscularis propria of the intestinal wall, with most infiltrating between 25 % and 50 % of the rectal circumference; 73 % of rectal nodules and 96 % of sigmoid nodules led to varying degrees of stenosis.  The concordance between intra-operative and pre-operative findings concerning the presence of rectal nodules was high, at 0.88 when associating CTC with MRI, whereas each imaging technique taken individually provided lower concordance coefficients.  In this study, 80.3 % of patients underwent the procedure that had been pre-operatively planned.  The authors concluded that the findings of this study suggested that associating MRI with CTC led to improved accuracy in pre-operative assessment of colorectal endometriosis and in subsequent pre-operative choice of surgical procedures on the digestive tract.

Multi-Target Stool DNA Versus CT Colonography for Colorectal Cancer Screening

Pickhardt and colleagues (2020) stated that multi-target stool DNA (mt-sDNA) screening has increased rapidly since simultaneous approval by the FDA and CMS in 2014, whereas CT colonography screening remains under-used and is not covered by CMS.  To report post-approval clinical experience with mt-sDNA screening for CRC and compare results with CT colonography screening at the same center.  In a retrospective, cohort study, asymptomatic adults underwent clinical mt-sDNA screening during a 5-year interval (2014 to 2019).  Electronic medical records were searched to verify test results and document subsequent optical colonoscopy and histopathologic findings.  A similar analysis was carried out for CT colonography screening during a 15-year interval (2004 to 2019), with consideration of thresholds for positivity of both 6-mm and 10-mm polyp sizes.  χ2 or 2-sample t tests were used for group comparisons.  A total of 3,987 asymptomatic adult patients (mean age of 64 years ± 9 [standard deviation]; 2,567 women) underwent mt-sDNA screening and 9,656 patients (mean age of 57 years ± 8; 5,200 women) underwent CT colonography.  Test-positive rates for mt-sDNA and for 6-mm- and 10-mm-threshold CT colonography were 15.2 %, 16.4 %, and 6.7 %, respectively.  Optical colonoscopy follow-up rates for positive results of mt-sDNA and 6-mm- and 10-mm-threshold CT colonography were 13.1 %, 12.3 %, and 5.9 %, respectively.  Positive predictive values (PPVs) for any neoplasm 6 mm or greater, advanced neoplasia, and CRC for mt-sDNA were 54.2 %, 22.7 %, and 1.9 % respectively; for 6-mm-threshold CT colonography, PPVs were 76.8 %, 44.3 %, and 2.7 %; for 10-mm-threshold CT colonography, PPVs were 84.5 %, 75.2 %, and 5.2 %, respectively (p < 0.001 for mt-sDNA versus CT colonography for all except 6-mm CRC at CT colonography).  For mt-sDNA versus 6-mm-threshold CT colonography, overall detection rates for advanced neoplasia were 2.7 % and 5.0 %, respectively (p < 0.001); corresponding detection rates for CRC were 0.23 % and 0.31 %, respectively (p = 0.43).  The authors concluded that the detection rates of advanced neoplasia at CT colonography screening were greater than those of multi-target stool DNA; detection rates were similar for colorectal cancer.

CT Colonography for Surveillance of Colorectal Cancer

Kuntz et al (2020) noted that surveillance following colorectal cancer (CRC) resection uses optical colonoscopy (OC) to detect intraluminal disease and CT to detect extra-colonic recurrence.  CT colonography (CTC) might be an efficient use of resources in this situation because it allows for intraluminal and extraluminal evaluations with 1 test.  These investigators developed a simulation model to compare lifetime costs and benefits for a cohort of patients with resected CRC.  Standard of care involved annual CT for 3 years and OC for years 1, 4 and every 5 years thereafter.  For the CTC-based strategy, these researchers replaced CT+OC at year 1 with CTC.  Patients with lesions greater than 6 mm detected by CTC underwent OC.  Detection of an adenoma 10 mm or larger was followed by OC at 1 year, then every 3 years thereafter.  Test characteristics and costs for CTC were derived from a clinical study.  Medicare costs were used for cancer care costs as well as alternative test costs.  The authors discounted costs and effects at 3 % per year.  For persons with resected stage-III CRC, the standard-of-care strategy was more costly (US$293) and effective (2.6 averted CRC cases and 1.1 averted cancer deaths per 1,000) than the CTC-based strategy, with an incremental cost-effectiveness ratio of US$55,500 per quality-adjusted life-year (QALY) gained.  This  analysis was most sensitive to the sensitivity of CTC for detecting polyps 10 mm or larger and assumptions regarding disease progression.  The authors concluded that in a simulation model, replacing the standard-of-care approach to post-diagnostic surveillance with a CTC-based strategy was not an efficient use of resources in most situations.

In addition, the European Society of Gastrointestinal Endoscopy (ESGE) and European Society of Gastrointestinal and Abdominal Radiology (ESGAR) guideline e on “Imaging alternatives to colonoscopy: CT colonography and colon capsule” (Spada et al, 2020) suggested that CTC with intravenous contrast medium injection for surveillance after curative-intent resection of colorectal cancer only in patients in whom colonoscopy is contraindicated or unfeasible.  Weak recommendation, low quality evidence.  There is insufficient evidence to recommend CCE in this setting (very low-quality evidence).

Furthermore, National Comprehensive Cancer Network’s clinical practice guidelines on “Colon cancer” (Version 2.2021) and “Rectal cancer” (Version 1.2021) do not mention CT colonography as a management tool.

CT / MRI Colonography Surveillance of Lynch Syndrome

van Liere et al (2022) stated that individuals with Lynch syndrome are at high risk for CRC.  Regular colonoscopies have proven to decrease CRC incidence and mortality; however, colonoscopy is burdensome and interval CRCs still occur.  Thus, an accurate, less-invasive screening method that guides the timing of colonoscopy would be of important value.  These researchers outlined the performance of non-endoscopic screening modalities for Lynch-associated CRC and adenomas.  They caried out a systematic literature search in Medline and Embase to identify studies examining imaging techniques and biomarkers for detection of CRC and adenomas in Lynch syndrome.  The QUADAS-2 tool was used for the quality assessment of included studies.  A total of 7 of 1,332 screened articles fulfilled the inclusion criteria; 2 studies evaluated either CT colonography or MR colonography; both techniques were unable to detect CRC and (advanced) adenomas of less than 10 mm.  The other 5 studies evaluated plasma methylated-SEPTIN9, fecal immunochemical test (FIT), fecal tumor DNA markers (BAT-26, hMLH1, p53, D9S171, APC, D9S162, IFNA and DCC) and fecal microbiome as screening modalities.  Sensitivity for CRC varied from 33 % (BAT-26) to 70 % (methylated-SEPTIN9) to 91 % (hMLH1).  High specificity (94 % to 100 %) for CRC and/or adenomas was observed for methylated-SEPTIN9, FIT and BAT-26.  Desulfovibrio was enriched in the stool of patients having adenomas.  However, all these studies were characterized by small populations, high/unclear risk of bias and/or low prevalence of adenomas.  The authors concluded that imaging techniques are unsuitable for colon surveillance in Lynch syndrome, whereas biomarkers are under-studied.  Having outlined biomarker research in Lynch-associated and sporadic CRC/adenomas, these researchers believed that these non-invasive markers may hold potential (whether or not combined) for this population.  As they could be of great value, (pre-)clinical studies in this field should be prioritized.

Furthermore, an UpToDate review on “Lynch syndrome (hereditary nonpolyposis colorectal cancer): Cancer screening and management” (Hall, 2022) does not mention CT / MRI colonography as a management option.

Magnetic Resonance Enterography for Monitoring Patients with Known Inflammatory Bowel Disease

Bruining et al (2018) noted that CT and MR enterography have become routine small bowel imaging tests to evaluate patients with established or suspected Crohn's disease (CD); however, the interpretation and use of these imaging modalities can vary widely.  A shared understanding of imaging findings, nomenclature, and utilization will improve the use of these imaging techniques to guide therapeutic options, as well as examine treatment response and complications.  Representatives from the Society of Abdominal Radiology (SAR) CD -- Focused Panel, the Society of Pediatric Radiology (SPR), the American Gastroenterological Association (AGA), and other experts, systematically evaluated evidence for imaging findings associated with small bowel CD enteric inflammation and established recommendations for the evaluation, interpretation, and use of CT and MR enterography in small bowel CD.  The authors made recommendations for imaging findings that indicate small bowel CD, how inflammatory small bowel CD and its complications should be described, elucidated potential extra-enteric findings that may be observed at imaging, and recommended that cross-sectional enterography should be considered in disease monitoring paradigms when small bowel disease or penetrating disease complications are present (Recommendation = Strong).

Lepus et al (2022) stated that ileocolonoscopy (IC) detects mucosal inflammation and MR enterography (MRE) detects transmural inflammation in CD.  In a retrospective review, these investigators examined the relationship between the simplified magnetic resonance index of activity (MARIAs) and measures of inflammation by IC in children with newly diagnosed CD.  This review entailed 140 patients aged 6 to 18 years with CD who had baseline IC and MRE within 5 weeks of diagnosis.  MARIAs was calculated for each intestinal segment (terminal ileum [TI], ascending colon, transverse colon, descending colon, sigmoid colon, rectum), defined as (1 × thickness of greater than 3 mm) + (1 × edema) + (1 × fat stranding) + (2 × ulcers).  Sensitivity and specificity were derived using receiver operating characteristic (ROC) curves to compare MARIAs to IC findings.  Using IC as the reference standard, the cut-off MARIAs of greater than or equal to 1 identified TI segments with active inflammation with 84 % sensitivity, 73 % specificity, 85 % PPV, 70 % NPV, and area under the curve (AUC) 0.782 (95 % CI: 0.689 to 0.876).  The cut-off MARIAs of greater than or equal to 2 identified TI segments with severe lesions with 87 % sensitivity, 76 % specificity, 87 % PPV, 76 % NPV, and AUC 0.814 (95 % CI: 0.712 to 0.916).  There was poor sensitivity for all colonic segments.  The authors concluded that MARIAs was feasible and accurate in reflecting disease activity in the TI, but not in the colon, in children with newly diagnosed CD.  These researchers stated that although the MARIAs may be useful for monitoring TI disease activity over time, full assessment continues to require both IC and MRE.

Ha et al (2022) noted that CT enterography (CTE) and MRE are considered substitutes for each other for evaluating CD; however, the adequacy of mixing them for routine periodic follow-up for CD has not been established.  In a retrospective study, these researchers compared MRE alone with the mixed use of CTE and MRE for the periodic follow-up of small bowel inflammation in patients with CD.  They compared 2 non-randomized groups, each comprising 96 patients with CD.  One group underwent CTE and MRE (MRE followed by CTE or vice-versa) for the follow-up of CD (interval, 13 to 27 months [median of 22 months]), and the other group underwent MRE alone (interval, 15 to 26 months [median of 21 months]).  However, these 2 groups were similar in clinical characteristics.  Three independent readers from 3 different institutions determined whether inflammation had decreased, remained unchanged, or increased within the entire small bowel and the terminal ileum based on sequential enterography of the patients after appropriate blinding.  These investigators compared the 2 groups for inter-reader agreement and accuracy (terminal ileum only) using endoscopy as the reference standard for enterographic interpretation.  The inter-reader agreement was greater in the MRE alone group for the entire small bowel (intraclass correlation coefficient [ICC]: 0.683 versus 0.473; p = 0.005) and the terminal ileum (ICC: 0.656 versus 0.490; p = 0.030).  The interpretation accuracy was higher in the MRE alone group without statistical significance (70.9 % to 74.5 % versus 57.9 % to 64.9 % in individual readers; adjusted odds ratio [OR] = 3.21; p = 0.077).  The authors concluded that the mixed use of CTE and MRE was inferior to MRE alone in terms of inter-reader reliability and could probably be less accurate than MRE alone for routine monitoring of small bowel inflammation in patients with CD; thus, the consistent use of MRE is favored for this purpose.

Furthermore, an UpToDate review on “Approach to functional gastrointestinal symptoms in adults with inflammatory bowel disease” (Gibson, 2022) states that “We obtain small bowel imaging for patients with a history of Crohn disease when active small bowel inflammation is suspected (e.g., chronic diarrhea, elevated CRP) but when ileocolonoscopy with biopsies does not demonstrate inflammation.  Several imaging modalities are available including computed tomography (CT) enterography, magnetic resonance (MR) enterography, capsule endoscopy, or gastrointestinal ultrasound.  We prefer MR enterography over CT enterography (although both have high sensitivities) for detecting active small bowel inflammation because MR enterography lacks radiation exposure and provides a detailed characterization of stenotic lesions”.

---

Appendix

Virtual colonoscopies should only be performed at centers with an appropriate generation of multi-detector CT scan – a minimum 4 detector CT scanner; collimation of 3 mm or less, overlapping sections at an interval that is 2/3 or less of the collimation, and scan times should be 30 seconds or less in order to minimize respiratory motion (Taskar et al, 1995; Scherer et al, 2008).  In addition, scans should be read by trained readers by virtue of having read least 30 CT scans (Halligan et al, 2005; ACR, 2006).

---

References